Which Way Should be Chosen for Treatment of Metastatic Renal Cell Carcinoma?_Crimson Publishers

Which Way Should be Chosen for Treatment of Metastatic Renal Cell Carcinoma? by Cemre Gündüz in Journal of Cancer Research

 

Crimson Publishers_ Novel Approaches in Cancer Study

There are two major pathways targeted for the treatment of metastatic renal cell cancer. One is VEGF inhibition that induces tumor shrinkage and increases progression-free survival and the other is Immune checkpoint inhibition that has been shown to increase overall survival. There are two clinically possible ways to block the antiangiogenic (VEGF) pathway. We can use Tyrosine kinase inhibitors (Sunitinib, Pazopanib, Cabozantinib, Axitinib, Sorafenib) that block the intracellular domain of the VEGFR or a monoclonal antibody (Bevacizumab) that binds to circulating VEGF and prevents it from activating VEGFR [1]. Checkpoint inhibition targeting the T lymphocyte-associated antigen 4 (CTLA-4) and/or programmed cell death receptor 1 (PD-1) pathway has led to significant improvements in the treatment of many malignancies, including renal cell carcinoma.

https://crimsonpublishers.com/nacs/fulltext/NACS.000563.php

please click on the link https://www.scilit.net/publisher/9410/10350

Comments

Post a Comment

Popular posts from this blog

Recent Advances in the Therapeutic Approaches of Glioblastoma Multiforme_Crimson Publishers

Image
  Recent Advances in the Therapeutic Approaches of Glioblastoma Multiforme by Siddharth Shah in  in Novel Approaches in Cancer Study Abstract Glioblastoma Multiforme (GBM, WHO grade IV) is one of the most aggressive, invasive, and lethal intracranial neoplasms, with a low post-diagnosis survival rate. Standard-of-care treatment regimens involving maximal surgical resection, radiotherapy, and genetic anti-tumor compounds like Temozolomide have only been marginally effective in improving overall survival and quality of life. Cell fusion, autophagy, and other complex biological processes affecting GBM pathophysiology are being studied to improve GBM treatment. This paper therefore focuses on oncolytic virus therapy combined with surgical resection, photodynamic therapy, and novel gene therapy, demonstrating how GBM treatment for patients could result in immediate and authentic tumor cytotoxicity and removal, rather than treatment of recurrent GBM. Standard therapy for GBM,...
Read more

Release of Inorganic Phosphate into the Tumor Environment: Possible Roles of Ecto- Nucleotidases and Ecto-Phosphatases

Abstract Inorganic phosphate (Pi) is essential for several biochemical reaction. Serum Pi is maintained at relatively narrow range concentrations, between 0.7 and 1.55mM. Tumor microenvironment presents a high Pi concentration (1.8±0.2mM Pi) and this could be associated wi the rapid growth in the “Growth Rate Hypothesis”. Several studies have identified high expression of Pi transporters in various tumor tissues. Similarly, ecto-enzymes (like ecto-nucleotidases or ecto- phosphates) act by dephosphorylating phosphosubstrates in the extracellular environment, and its high expression has been observed in various types of cancer. Little is known about the function of these ecto-enzymes on Pi releasing and accumulation in the tumor environment. Therefore, the purpose of this study is to correlate a possible contribution of the Pi release in the tumor microenvironment by ecto-nucleotidases and ecto-phosphatases, concomitant to the regulation of Pi extracellular pool by specific Pi...
Read more

Release of Inorganic Phosphate into the Tumor Environment: Possible Roles of Ecto- Nucleotidases and Ecto-Phosphatases_Crimson Publishers

Image
Release of Inorganic Phosphate into the Tumor Environment: Possible Roles of Ecto- Nucleotidases and Ecto-Phosphatases by Marco Antonio Lacerda-Abreu and José Roberto Meyer- Fernandes in Journal of Cancer Research Crimson Publishers _  Novel Approaches in Cancer Study Inorganic phosphate (Pi) is essential for several biochemical reaction. Serum Pi is maintained at relatively narrow range concentrations, between 0.7 and 1.55mM. Tumor microenvironment presents a high Pi concentration (1.8±0.2mM Pi) and this could be associated wi the rapid growth in the “Growth Rate Hypothesis”. Several studies have identified high expression of Pi transporters in various tumor tissues. Similarly, ecto-enzymes (like ecto-nucleotidases or ecto- phosphates) act by dephosphorylating phosphosubstrates in the extracellular environment, and its high expression has been observed in various types of cancer. Little is known about the function of these ecto-enzymes on Pi releasing and accumulation in the tu...
Read more